Skip to main content
SpringerLink
Log in

BRCA1 Cross-Talk with Hormone Receptors

  • Chapter
  • First Online:
Hormone Receptors in Breast Cancer

Part of the book series: Cancer Treatment and Research ((CTAR,volume 147))

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994;266:66–71.

    PubMed  CAS  Google Scholar 

  2. Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, Collins N, Gregory S, Gumbs C, Micklem G. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995;378:789–792.

    PubMed  CAS  Google Scholar 

  3. Tavtigian SV, Simard J, Rommens J, Couch F, Shattuck-Eidens D, Neuhausen S, Merajver S, Thorlacius S, Offit K, Stoppa-Lyonnet D, Belanger C, Bell R, Berry S, Bogden R, Chen Q, Davis T, Dumont M, Frye C, Hattier T, Jammulapati S, Janecki T, Jiang P, Kehrer R, Leblanc JF, Goldgar DE, et al. The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat Genet 1996;12:333–337.

    PubMed  CAS  Google Scholar 

  4. Merajver SD, Frank TS, Xu J, Pham TM, Calzone KA, Bennett-Baker P, Chamberlain J, Boyd J, Garber JE, Collins FS et al. Germline BRCA1 mutations and loss of the wild-type allele in tumors from families with early onset breast and ovarian cancer. Clin Cancer Res. 1995;1:539–544.

    PubMed  CAS  Google Scholar 

  5. Rosen EM, Fan S, Pestell RG, Goldberg ID. BRCA1 gene in breast cancer. J Cell Physiol. 2003;196:19–41.

    PubMed  CAS  Google Scholar 

  6. Gudmundsdottir K, Ashworth A. The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability. Oncogene 2006;25:5864–5874 Review.

    PubMed  CAS  Google Scholar 

  7. Tirkkonen M, Johannsson O, Agnarsson BA, Olsson H, Ingvarsson S, Karhu R, Tanner M, Isola J, Barkardottir RB, Borg A, Kallioniemi OP. Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations. Cancer Res. 1997;57:1222–1227.

    PubMed  CAS  Google Scholar 

  8. Xu X, Weaver Z, Linke SP, Li C, Gotay J, Wang XW, Harris CC, Ried T, Deng CX. Centrosome amplification and a defective G2-M cell cycle checkpoint induce genetic instability in BRCA1 exon 11 isoform-deficient cells. Mol Cell. 1999;3:389–395.

    PubMed  CAS  Google Scholar 

  9. Weaver Z, Montagna C, Xu X, Howard T, Gadina M, Brodie SG, Deng CX, Ried T. Mammary tumors in mice conditionally mutant for Brca1 exhibit gross genomic instability and centrosome amplification yet display a recurring distribution of genomic imbalances that is similar to human breast cancer. Oncogene 2002;21:5097–5107.

    PubMed  CAS  Google Scholar 

  10. Thompson D, Easton DF Breast Cancer Linkage Consortium. Cancer Incidence in BRCA1 mutation carriers. J Natl Cancer Inst. 2002;94:1358–1365.

    PubMed  CAS  Google Scholar 

  11. Elson DA, Riley RR, Lacey A, Thordarson G, Talamantes FJ, Arbeit JM. Sensitivity of the cervical transformation zone to estrogen-induced squamous carcinogenesis. Cancer Res. 2000;60:1267–1275.

    PubMed  CAS  Google Scholar 

  12. Arbeit JM, Howley PM, Hanahan D. Chronic estrogen-induced cervical and vaginal squamous carcinogenesis in human papillomavirus type 16 transgenic mice. Proc Nat Acad Sci USA. 2003;93:2930–2935.

    Google Scholar 

  13. de Villiers EM. Relationship between steroid hormone contraceptives and HPV, cervical intraepithelial neoplasia and cervical carcinoma. Int J Cancer. 2003;103:705–758.

    PubMed  Google Scholar 

  14. Liede A, Karlan BY, Narod SA. Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature. J Clin Oncol. 2004;22: 735–742.

    PubMed  CAS  Google Scholar 

  15. Lubinski J, Phelan CM, Ghadirian P, Lynch HT, Garber J, Weber B, Tung N, Horsman D, Isaacs C, Monteiro AN, Sun P, Narod SA. Cancer variation associated with the position of the mutation in the BRCA2 gene. Familial Cancer. 2004;3:1–10.

    PubMed  CAS  Google Scholar 

  16. Narod SA. Modifiers of risk of hereditary breast cancer. Oncogene 2006;25:5832–5836 Review.

    PubMed  CAS  Google Scholar 

  17. Rosen EM, Fan S, Isaacs C. BRCA1 in hormonal carcinogenesis: basic and clinical research. Endocr Relat Cancer. 2005;12:533–548 Review.

    PubMed  CAS  Google Scholar 

  18. Rebbeck TR, Lynch HT, Neuhausen SL, Narod SA, Van’t Veer L, Garber JE, Evans G, Isaacs C, Daly MB, Matloff E, Olopade OI, Weber BL; Prevention and Observation of Surgical End Points Study Group. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. New Engl J Med 2002;346:1616–1622.

    PubMed  Google Scholar 

  19. Kauff ND, Domchek SM, Friebel TM, Robson ME, Lee J, Garber JE, Isaacs C, Evans DG, Lynch H, Eeles RA, Neuhausen SL, Daly MB, Matloff E, Blum JL, Sabbatini P, Barakat RR, Hudis C, Norton L, Offit K, Rebbeck TR. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol 2008;26:1331–1337.

    PubMed  Google Scholar 

  20. Monteiro AN, August A, Hanafusa H. Evidence for a transcription activation function of BRCA1 C-terminal region. Proc Nat Acad Sci USA 1996;93:13595–13599.

    Google Scholar 

  21. Hashizume R, Fukuda M, Maeda I, Nishikawa H, Oyake D, Yabuki Y, Ogata H, Ohta T. The RING heterodimer BRCA1–BARD1 is a ubiquitin ligase inactivated by a breast cancer-derived mutation. J Biol Chem. 2001;276:14537–14540.

    Google Scholar 

  22. Boulton SJ. BRCA1-mediated ubiquitylation. Cell Cycle. 2006;5:1481–1486.

    PubMed  CAS  Google Scholar 

  23. Shakya R, Szabolcs M, McCarthy E, Ospina E, Basso K, Nandula S, Murty V, Baer R, Ludwig T. The basal-like mammary carcinomas induced by Brca1 or Bard1 inactivation implicate the BRCA1/BARD1 heterodimer in tumor suppression. Proc Nat Acad Sci USA 2008; Apr 28. [Epublished ahead of print].

    Google Scholar 

  24. Bork P, Hofmann K, Bucher P, Neuwald AF, Altschul SF, Koonin EV. A superfamily of conserved domains in DNA damage-responsive cell cycle checkpoint proteins. FASEB J. 1997;11:68–76.

    PubMed  CAS  Google Scholar 

  25. Thakur S, Zhang HB, Peng Y, Le H, Carroll B, Ward T, Yao J, Farid LM, Couch FJ, Wilson RB, Weber BL. Localization of BRCA1 and a splice variant identifies the nuclear localization signal. Mol Cell Biol. 1997;17:444–452.

    PubMed  CAS  Google Scholar 

  26. Rodriguez JA, Henderson BR. Identification of a functional nuclear export sequence in BRCA1. J Biol Chem. 2000;275: 38589–38596.

    PubMed  CAS  Google Scholar 

  27. Rajan JV, Wang M, Marquis ST, Chodosh LA. Brca2 is coordinately regulated with Brca1 during proliferation and differentiation in mammalian epithelial cells. Proc Nat Acad Sci USA 1996;93:3078–3083.

    Google Scholar 

  28. Thomas JE, Smith M, Tonkinson JL, Rubinfeld B, Polakis P Induction of phosphorylation of BRCA1 during the cell cycle and after DNA damage. Cell Growth Differen. 1997;8:801–809.

    CAS  Google Scholar 

  29. Rosen EM, Fan S, Ma Y. BRCA1 regulation of transcription. Cancer Lett. 2006;236:175–185 Review.

    PubMed  CAS  Google Scholar 

  30. Hu YF, Li R. JunB potentiates function of BRCA1 activation domain 1 (AD1) through a coiled-coil-mediated interaction. Genes Dev. 2002;16:1509–1517.

    PubMed  CAS  Google Scholar 

  31. Fan S, Wang J, Yuan R, Ma Y, Meng Q, Erdos MR, Pestell RG, Yuan F, Auborn KJ, Goldberg ID, Rosen EM. BRCA1 inhibition of estrogen receptor signaling in transfected cells. Science 1999;284:1354–1356.

    PubMed  CAS  Google Scholar 

  32. Zhang Y, Fan S, Meng Q, Ma Y, Katiyar P, Schlegel R, Rosen EM. BRCA1 interaction with human papillomavirus oncoproteins. J Biol Chem. 2005;280:33165–33177.

    Google Scholar 

  33. Fan S, Ma YX, Wang C, Yuan RQ, Meng Q, Wang JA, Erdos M, Goldberg ID, Webb P, Kushner PJ, Pestell RG, Rosen EM p300 Modulates the BRCA1 inhibition of estrogen receptor activity. Cancer Res. 2002;62:141–151.

    PubMed  CAS  Google Scholar 

  34. Fan S, Ma YX, Wang C, Yuan RQ, Meng Q, Wang JA, Erdos M, Goldberg ID, Webb P, Kushner PJ, Pestell RG, Rosen EM. Role of direct interaction in BRCA1 inhibition of estrogen receptor activity. Oncogene 2001;20:77–87.

    PubMed  CAS  Google Scholar 

  35. Fan S, Wang JA, Yuan RQ, Ma YX, Meng Q, Erdos MR, Brody LC, Goldberg ID, Rosen EM. BRCA1 as a potential human prostate tumor suppressor: modulation of proliferation, damage responses and expression of cell regulatory proteins. Oncogene 1998;16:3069–3082.

    PubMed  CAS  Google Scholar 

  36. Fan S, Yuan R, Ma YX, Meng Q, Goldberg ID, Rosen EM Mutant BRCA1 genes antagonize phenotype of wild type BRCA1. Oncogene 2001;20:8215–8235.

    PubMed  CAS  Google Scholar 

  37. Kawai H, Li H, Chun P, Avraham S, Avraham HK Direct interaction between BRCA1 and the estrogen receptor regulates vascular endothelial growth factor (VEGF) transcription and secretion in breast cancer cells. Oncogene 2002;21:7730–7739.

    PubMed  CAS  Google Scholar 

  38. Ma YX, Tomita Y, Fan S, Wu K, Tong Y, Zhao Z, Song LN, Goldberg ID, Rosen EM. Structural determinants of the BRCA1: estrogen receptor interaction. Oncogene 2005;24:1831–1846.

    PubMed  CAS  Google Scholar 

  39. Wu LC, Wang ZW, Tsan JT, Spillman MA, Phung A, Xu XL, Yang MC, Hwang LY, Bowcock AM, Baer R. Identification of a RING protein that can interact in vivo with the BRCA1 gene product. Nat Genet. 1996;14:430–440.

    PubMed  CAS  Google Scholar 

  40. Ruffner H, Joazeiro CA, Hemmati D, Hunter T, Verma IM. Cancer-predisposing mutations within the RING domain of BRCA1: loss of ubiquitin protein ligase activity and protection from radiation hypersensitivity. Proc Nat Acad Sci USA. 2001;98:5134–5139.

    PubMed  CAS  Google Scholar 

  41. Eakin CM, Maccoss MJ, Finney GL, Klevit RE. Estrogen receptor alpha is a putative substrate for the BRCA1 ubiquitin ligase. Proc Nat Acad Sci USA. 2007;104:5794–5799.

    PubMed  CAS  Google Scholar 

  42. Pedram A, Razandi M, Levin ER. Nature of functional estrogen receptors at the plasma membrane. Mol Endocrinol. 2006;20:1996–2009.

    PubMed  CAS  Google Scholar 

  43. Razandi M, Pedram A, Rosen EM, Levin ER. BRCA1 inhibits membrane estrogen and growth factor receptor signaling to cell proliferation in breast cancer. Mol Cell Biol. 2004;24:5900–5913.

    PubMed  CAS  Google Scholar 

  44. Zheng L, Annab LA, Afshari CA, Lee WH, Boyer TG. BRCA1 mediates ligand-independent transcriptional repression of the estrogen receptor. Proc Nat Acad Sci USA. 2001;98:9587–9592.

    PubMed  CAS  Google Scholar 

  45. Jones LP, Li M, Halama ED, Ma Y, Lubet R, Grubbs CJ, Deng C-X, Rosen EM, Furth PA. Promotion of mammary cancer development by tamoxifen in a mouse model of Brca1-mutation related breast cancer. Oncogene 2005;24:3554–3562.

    PubMed  CAS  Google Scholar 

  46. Ma Y, Hu C, Riegel AT, Fan S, Rosen EM. Growth factor signaling pathways modulate BRCA1 repression of estrogen receptor-alpha activity. Mol Endocrinol. 2007;21:1905–1923.

    PubMed  CAS  Google Scholar 

  47. Mosselman S, Polman J, Dijkema R. ER-beta: identification and characterization of a novel human estrogen receptor. FEBS Lett. 1996;392:49–53.

    PubMed  CAS  Google Scholar 

  48. Pettersson K, Delaunay F, Gustafsson JA. Estrogen receptor beta acts as a dominant regulator of estrogen signaling. Oncogene 2000;19:4970–4978.

    PubMed  CAS  Google Scholar 

  49. Weihua Z, Saji S, Makinen S, Cheng G, Jensen EV, Warner M, Gustafsson JA. Estrogen receptor (ER) beta, a modulator of ER alpha in the uterus. Proc Nat Acad Sci USA. 2000;97:5936–5941.

    PubMed  CAS  Google Scholar 

  50. Jisa E, Jungbauer A. Kinetic analysis of estrogen receptor homo- and heterodimerization in vitro. J Steroid Biochem Mol Biol. 2003;84:141–148.

    PubMed  CAS  Google Scholar 

  51. Hall JM, McDonnell DP. The estrogen receptor betaisoform (ERbeta) of the human estrogen receptor modulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. Endocrinology 1999;140:5566–5578.

    PubMed  CAS  Google Scholar 

  52. Hu Y, Ghosh S, Amleh A, Yue W, Lu Y, Katz A, Li R. Modulation of aromatase expression by BRCA1: a possible link to tissue-specific tumor suppression. Oncogene 2005;24:8343–8348.

    PubMed  CAS  Google Scholar 

  53. Lu M, Chen D, Lin Z, Reierstad S, Trauernicht AM, Boyer TG, Bulun SE. BRCA1 negatively regulates the cancer-associated aromatase promoters I.3 and II in breast adipose fibroblasts and malignant epithelial cells. J Clin Endocrinol Metab. 2006;91:4514–4519.

    PubMed  CAS  Google Scholar 

  54. Subbaramaiah K, Hudis C, Chang SH, Hla T, Dannenberg AJ. EP2 and EP4 receptors regulate aromatase expression in human adipocytes and breast cancer cells. Evidence of a BRCA1 and p300 exchange. J Biol Chem. 2008;283:3433–3444.

    PubMed  CAS  Google Scholar 

  55. Ma Y, Katiyar P, Jones LP, Fan S, Zhang Y, Furth PA, Rosen EM. The breast cancer susceptibility gene BRCA1 regulates progesterone receptor signaling in mammary epithelial cells. Mol Endocrinol. 2006;20:14–34.

    PubMed  CAS  Google Scholar 

  56. Poole AJ, Li Y, Kim Y, Lin SC, Lee WH, Lee EY. Prevention of Brca1-mediated mammary tumorigenesis in mice by a progesterone antagonist. Science 2006;314:1467–1470.

    PubMed  CAS  Google Scholar 

  57. Henderson BE, Feigelson HS Hormonal carcinogenesis. Carcinogenesis 2000;21:427–433.

    PubMed  CAS  Google Scholar 

  58. von Schoultz B. Androgens and the breast. Maturitas 2007;57:47–49 Review.

    Google Scholar 

  59. Park JJ, Irvine RA, Buchanan G, Koh SS, Park JM, Tilley WD, Stallcup MR, Press MF, Coetzee GA. Breast cancer susceptibility gene 1 (BRCA1) is a coactivator of the androgen receptor. Cancer Res. 2000;60:5946–5949.

    PubMed  CAS  Google Scholar 

  60. Yeh S, Hu YC, Rahman M, Lin HK, Hsu CL, Ting HJ, Kang HY, Chang C. Increase of androgen induced cell death and androgen receptor transactivation by BRCA1 in prostate cancer cells. Proc Nat Acad Sci USA. 2000;97:11256–11261.

    Google Scholar 

  61. Ando S, De Amicis F, Rago V, Carpino A, Maggiolini M, Panno ML, Lanzino M. Breast cancer: from estrogen to androgen receptor. Mol Cell Endocrinol. 2002;193:121–128.

    PubMed  CAS  Google Scholar 

  62. Ferro P, Catalano MG, Dell’Eva R, Fortunati N, Pfeffer U. The androgen receptor CAG repeat: a modifier of carcinogenesis? Mol Cell Endocrinol. 2002;193:109–120.

    PubMed  CAS  Google Scholar 

  63. Hakem R, de la Pompa JL, Mak TW. Developmental studies of Brca1 and Brca2 knock-out mice. J Mammary Gland Biol Neoplasia. 1998;3: 431–445 Review.

    PubMed  CAS  Google Scholar 

  64. Hakem R, de la Pompa JL, Elia A, Potter J, Mak TW. Partial rescue of Brca1 (5–6) early embryonic lethality by p53 or p21 null mutation. Nat Genet. 1997;16:298–302.

    PubMed  CAS  Google Scholar 

  65. Lane TF, Deng C, Elson A, Lyu MS, Kozak CA, Leder P. Expression of Brca1 is associated with terminal differentiation of ectodermally and mesodermally derived tissues in mice. Genes Dev. 1995;9:2712–2722.

    PubMed  CAS  Google Scholar 

  66. Marquis ST, Rajan JV, Wynshaw-Boris A, Xu J, Yin GY, Abel KJ, Weber BL, Chodosh LA. The developmental pattern of Brca1 expression implies a role in differentiation of the breast and other tissues. Nat Genet. 1995;11:17–26.

    PubMed  CAS  Google Scholar 

  67. Kubista M, Rosner M, Kubista E, Bernaschek G, Hengstschlager M. Brca1 regulates in vitro differentiation of mammary epithelial cells. Oncogene 2002;21:4747–4756.

    PubMed  CAS  Google Scholar 

  68. Furuta S, Jiang X, Gu B, Cheng E, Chen PL, Lee WH. Depletion of BRCA1 impairs differentiation but enhances proliferation of mammary epithelial cells. Proc Nat Acad Sci USA. 2005;102:9176–9181.

    PubMed  CAS  Google Scholar 

  69. Rajan JV, Marquis ST, Gardner HP, Chodosh LD. Developmental expression of Brca2 colocalizes with Brca1 and is associated with proliferation and differentiation in multiple tissues. Devel Biol. 1997;184:385–40.

    CAS  Google Scholar 

  70. Bennett LM, McAllister KA, Malphurs J, Ward T, Collins NK, Seely JC, Gowen LC, Koller BH, Davis BJ, Wiseman RW. Mice heterozygous for a Brca1 or Brca2 mutation display distinct mammary gland and ovarian phenotypes in response to diethylstilbestrol. Cancer Res. 2000;60:3461–3469.

    PubMed  CAS  Google Scholar 

  71. Xu X, Wagner K-U, Larson D, Weaver Z, Li C, Ried T, Hennighausen L, Wynshaw-BorisA, Deng C-X Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation. Nat Genet. 1999;22: 37–43.

    PubMed  CAS  Google Scholar 

  72. Phillips KA, Andrulis IL, Goodwin PJ Breast carcinomas arising in carriers of mutations in BRCA1 or BRCA2 are they prognostically different? J Clin Oncol. 1999;17:3653–3663.

    PubMed  CAS  Google Scholar 

  73. Lakhani SR, Van De Vijver MJ, Jacquemier J, Anderson TJ, Osin PP, McGuffog L, Easton DF. The pathology of familial breast cancer predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol. 2002;20:2310–2318.

    PubMed  CAS  Google Scholar 

  74. Brodie SG, Xu X, Qiao W, Li WM, Cao L, Deng CX Multiple genetic changes are associated with mammary tumorigenesis in Brca1 conditional knockout mice. Oncogene 2001;20:17514–17523.

    Google Scholar 

  75. Deng CX Tumor formation in Brca1 conditional mutant mice. Environ Mol Mutagen. 2002;39:171–177.

    PubMed  CAS  Google Scholar 

  76. Jones LP, Tilli MT, Assefnia S, Torre K, Halama ED, Parrish A, Rosen EM, Furth PA. Activation of estrogen signaling pathways collaborates with loss of Brca1 to promote development of ERalpha-negative and ERalpha-positive mammary preneoplasia and cancer. Oncogene 2008;27:794–802.

    PubMed  CAS  Google Scholar 

  77. Bachelier R, Xu X, Li C, Qiao W, Furth PA, Lubet RA, Deng CX. Effect of bilateral oophorectomy on mammary tumor formation in BRCA1 mutant mice. Oncol Rep. 2005;14:1117–1120.

    PubMed  Google Scholar 

  78. Holmes MD, Willett WC Does diet affect breast cancer risk? Breast Cancer Res. 2004;6:170–178.

    PubMed  CAS  Google Scholar 

  79. Linos E, Willett WC. Diet and breast cancer risk reduction. J Natl Compr Canc Netw. 2007;5:711–718 Review.

    PubMed  Google Scholar 

  80. Fan S, Meng Q, Gao B, Grossman J, Yadegari M, Goldberg ID, Rosen EM. Alcohol stimulates estrogen receptor signaling in human breast cancer cell lines. Cancer Res. 2000;60:5635–5639.

    PubMed  CAS  Google Scholar 

  81. Rattenborg T, Gjermandsen I, Bonefeld-Jorgensen EC. Inhibition of E2-induced expression of BRCA1 by persistent organochlorines. Breast Cancer Res. 2007;4:R12.

    Google Scholar 

  82. Jeffy BD, Chirnomas RB, Chen EJ, Gudas JM, Romagnolo DF. Activation of the aromatic hydrocarbon receptor pathway is not sufficient for transcriptional repression of BRCA-1: requirements for metabolism of benzo[a]pyrene to 7r,8t-dihydroxy-9t,10-epoxy-7,8,9,10-tetrahydrobenzo[a]pyrene. Cancer Res. 2002;62:113–121.

    PubMed  CAS  Google Scholar 

  83. Hockings JK, Thorne PA, Kemp MQ, Morgan SS, Selmin O, Romagnolo DF. The ligand status of the aromatic hydrocarbon receptor modulates transcriptional activation of BRCA-1 promoter by estrogen. Cancer Res. 2006;66:2224–2232.

    PubMed  CAS  Google Scholar 

  84. Kang HJ, Kim HJ, Kim SK, Barouki R, Cho CH, Khanna KK, Rosen EM, Bae I. BRCA1 modulates xenobiotic stress-inducible gene expression by interacting with ARNT in human breast cancer cells. J Biol Chem. 2006;281: 14654–14662.

    PubMed  CAS  Google Scholar 

  85. Shertzer HG, Senft AP. The micronutrient indole-3-carbinol: implications for disease and chemoprevention. Drug Metab Drug Interact. 2000;17:159–188.

    CAS  Google Scholar 

  86. Bradlow HL, Michnovich J, Telang NT, Osborne MP. Effects of dietary indole-3-carbinol on estradiol metabolism and spontaneous mammary tumors in mice. Carcinogenesis 1991;12:1571–1574.

    PubMed  CAS  Google Scholar 

  87. Meng Q, Yuan F, Goldberg ID, Rosen EM, Auborn K, Fan S. Indole-3-carbinol is a negative regulator of estrogen receptor-alpha signaling in human tumor cells. J Nutr. 2000;130:2927–2931.

    PubMed  CAS  Google Scholar 

  88. Meng Q, Qi M, Chen DZ, Yuan R, Goldberg ID, Rosen EM, Auborn K, Fan S. Suppression of breast cancer invasion and migration by indole-3-carbinol: associated with up-regulation of BRCA1 and E-cadherin/catenin complexes. J Mol Med. 2000;78:155–165.

    PubMed  CAS  Google Scholar 

  89. Carter TH, Liu K, Ralph W Jr, Chen D, Qi M, Fan S, Yuan F, Rosen EM, Auborn KJ Diindolylmethane alters gene expression in human keratinocytes in vitro. J Nutr. 2002;132:3314–3324.

    PubMed  CAS  Google Scholar 

  90. Fan S, Meng Q, Auborn K, Carter T, Rosen EM BRCA1 and BRCA2 as molecular targets for phytochemicals indole-3-carbinol and genistein in breast and prostate cancer cells. Br J Cancer. 2006;94:407–426.

    PubMed  CAS  Google Scholar 

  91. Cabanes A, Wang M, Olivo S, DeAssis S, Gustafsson JA, Khan G, Hilakivi-Clarke L. Prepubertal estradiol and genistein exposures up-regulate BRCA1 mRNA and reduce mammary tumorigenesis. Carcinogenesis 2004;25:741–748.

    PubMed  CAS  Google Scholar 

  92. Barkhem T, Carlsson B, Nilsson Y, Enmark E, Gustafsson J, Nilsson S. Differential response of estrogen receptor alpha and estrogen receptor beta to partial estrogen agonists/antagonists. Mol Pharmacol. 1998;54:105–112.

    PubMed  CAS  Google Scholar 

  93. Pike AC, Brzozowski AM, Hubbard RE, Bonn T, Thorsell AG, Engstrom O, Ljunggren J, Gustafsson JA, Carlquist M Structure of the ligand-binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist. EMBO J. 1999;18:4608–4618.

    PubMed  CAS  Google Scholar 

  94. Yu B, Khan G, Foxworth A, Huang K, Hilakivi-Clarke L. Maternal dietary exposure to fiber during pregnancy and mammary tumorigenesis among rat offspring. Int J Cancer. 2006;119: 2279–2286.

    PubMed  CAS  Google Scholar 

  95. Hilakivi-Clarke L, Olivo SE, Shajahan A, Khan G, Zhu Y, Zwart A, Cho E, Clarke R. Mechanisms mediating the effects of prepubertal (n-3) polyunsaturated fatty acid diet on breast cancer risk in rats. J Nutr. 2005;135(12 Suppl):2946S–2952S Review.

    PubMed  CAS  Google Scholar 

  96. Verhoog LC, Brekelmans CT, Seynaeve C, van den Bosch LM, Dahmen G, van Geel AN, Tilanus-Linthorst MM, Bartels CC, Wagner A, van den Ouweland A, Devilee P, Meijers-Heijboer EJ, Klijn JG. Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1. Lancet 1998;351:316–321.

    PubMed  CAS  Google Scholar 

  97. Robson ME, Chappuis PO, Satagopan J, Wong N, Boyd J, Goffin JR, Hudis C, Roberge D, Norton L, Begin LR, Offit K, Foulkes WD. A combined analysis of outcome following breast cancer differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment. Breast Cancer Res. 2004;6:R8–R17.

    Google Scholar 

  98. Reis-Filho JS, Tutt AN. Triple negative tumours: a critical review. Histopathology 2008;52:108–118 Review.

    PubMed  CAS  Google Scholar 

  99. Archey WB, McEachern KA, Robson M, Offit K, Vaziri SA, Casey G, Borg A, Arrick BA. Increased CpG methylation of the estrogen receptor gene in BRCA1-linked estrogen receptor-negative breast cancers. Oncogene 2002;21:7034–7041.

    PubMed  CAS  Google Scholar 

  100. Hosey AM, Gorski JJ, Murray MM, Quinn JE, Chung WY, Stewart GE, James CR, Farragher SM, Mulligan JM, Scott AN, Dervan PA, Johnston PG, Couch FJ, Daly PA, Kay E, McCann A, Mullan PB, Harkin DP. Molecular basis for estrogen receptor alpha deficiency in BRCA1-linked breast cancer. J Natl Cancer Inst. 2007;99:1683–1694.

    PubMed  CAS  Google Scholar 

  101. Ozcelik H, To MD, Couture J, Bull SB, Andrulis IL. Preferential allelic expression can lead to reduced expression of BRCA1 in sporadic breast cancers. Int J Cancer. 1998;77:1–6.

    PubMed  CAS  Google Scholar 

  102. Taylor J, Lymboura M, Pace PE, A’hern RP, Desai AJ, Shousha S, Coombes RC, Ali S. An important role for BRCA1 in breast cancer progression is indicated by its loss in a large proportion of nonfamilial breast cancers. Int J Cancer. 1998;79:334–342.

    PubMed  CAS  Google Scholar 

  103. Rio PG, Maurizis JC, Peffault de Latour M, Bignon YJ, Bernard-Gallon DJ. Quantification of BRCA1 protein in sporadic breast carcinoma with or without loss of heterozygosity of the BRCA1 gene. Int J Cancer. 1999;80:823–826.

    PubMed  CAS  Google Scholar 

  104. Wilson CA, Ramos L, Villasenor MR, Anders KH, Press MF, Clarke K, Karlan B, Chen JJ, Scully R, Livingston D, Zuch RH, Kanter MH, Cohen S, Calzone FJ, Slamon DJ. Localization of human BRCA1 and its loss in high-grade, non-inherited breast carcinomas. Nat Genet. 1999;21:236–240.

    PubMed  CAS  Google Scholar 

  105. Rice JC, Massey-Brown KS, Futscher BW. Aberrant methylation of the BRCA1 CpG island promoter is associated with decreased BRCA1 mRNA in sporadic breast cancer cells. Oncogene 1998;17:1807–1812.

    PubMed  CAS  Google Scholar 

  106. Esteller M, Silva JM, Dominguez G, Bonilla F, Matias-Guiu X, Lerma E, Bussaglia E, Prat J, Harkes IC, Repasky EA, Gabrielson E, Schutte M, Baylin SB, Herman JG. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst. 2000;92:564–569.

    PubMed  CAS  Google Scholar 

  107. Staff S, Isola J, Tanner M Haplo-insufficiency of BRCA1 in sporadic breast cancer. Cancer Res. 2003;63:4978–4983.

    PubMed  CAS  Google Scholar 

  108. Butcher DT, Rodenhiser DI. Epigenetic inactivation of BRCA1 is associated with aberrant expression of CTCF and DNA methyltransferase (DNMT3B) in some sporadic breast tumours. Eur J Cancer. 2007;43:210–219.

    PubMed  CAS  Google Scholar 

  109. MacDonald G, Stramwasser M, Mueller CR. Characterization of a negative transcriptional element in the BRCA1 promoter. Breast Cancer Res. 2007;9:R49.

    PubMed  Google Scholar 

  110. Wang C, Fan S, Li Z, Fu M, Rao M, Ma Y, Lisanti MP, Albanese C, Katzenellenbogen BS, Kushner PJ, Weber B, Rosen EM, Pestell RG. Cyclin D1 antagonizes BRCA1 repression of estrogen receptor alpha activity. Cancer Res. 2005;65:6557–6567.

    PubMed  CAS  Google Scholar 

Download references

Acknowledgments

Dr. Rosen has been supported, in part, by USPHS grants R01-CA82599, RO1-CA80000, and RO1-CA104546.

Author information

Authors and Affiliations

  1. Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Box 571469, 3970 Reservoir Road, NW, Washington, DC 20057-1469, USA

    Eliot M. Rosen

Authors
  1. Eliot M. Rosen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yongxian Ma
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Saijun Fan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eliot M. Rosen .

Editor information

Editors and Affiliations

  1. Baylor College of Medicine, Baylor Plaza 1, Houston, 77030, U.S.A.

    Suzanne A. W. Fuqua

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Rosen, E.M., Ma, Y., Fan, S. (2009). BRCA1 Cross-Talk with Hormone Receptors. In: Fuqua, S. (eds) Hormone Receptors in Breast Cancer. Cancer Treatment and Research, vol 147. Springer, Boston, MA. https://doi.org/10.1007/978-0-387-09463-2_5

Download citation

  • DOI: https://doi.org/10.1007/978-0-387-09463-2_5

  • Published:

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-0-387-09462-5

  • Online ISBN: 978-0-387-09463-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation